RTP Mobile Logo
Expert Second Opinion: The Emerging Role of Immunotherapy and Targeted Treatment in Localized Non-Small Cell Lung Cancer (Webinar Audio Proceedings)
Released October 2021

Featuring perspectives from Drs Edward Garon, Jarushka Naidoo, Harvey Pass and Heather Wakelee. Published October 14, 2021. (Webinar Audio Proceedings)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).

    LEARNING OBJECTIVES

    • Assess the anticipated benefits, risks and long-term outcomes associated with the use of adjuvant and neoadjuvant therapy in the management of Stage IB to IIIA non-small cell lung cancer (NSCLC), and consider this information when counseling patients regarding current therapeutic recommendations.
    • Evaluate available data documenting the efficacy and safety of anti-PD-1/PD-L1 antibodies, and appropriately identify patients who may benefit from adjuvant or neoadjuvant immune checkpoint inhibition.
    • Appreciate emerging Phase III findings with the use of an anti-PD-L1 antibody after the completion of chemotherapy and surgery for patients with resectable NSCLC, and consider the potential effect of this information on current and future clinical practice.
    • Evaluate the clinical relevance of the various genomic abnormalities found in patients with localized NSCLC, and appreciate available and emerging data attempting to validate the efficacy of targeted therapy in these individuals.
    • Recall the design of ongoing clinical trials evaluating immune checkpoint inhibitor therapy for patients with localized NSCLC, and counsel appropriate patients about availability and participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.75 (audio) and 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/WCLC2021/EarlyStageNSCLC/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/WCLC2021/EarlyStageNSCLC/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/WCLC2021/EarlyStageNSCLC/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/WCLC2021/EarlyStageNSCLC.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Edward B Garon, MD, MS
    Professor
    Director, Thoracic Oncology Program
    Director, Signal Transduction and Therapeutics Research Program
    David Geffen School of Medicine at UCLA
    Jonsson Comprehensive Cancer Center
    Los Angeles, California

    Consulting Agreements: ABL Bio, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Dracen Pharmaceuticals, Eisai Inc, EMD Serono Inc, GlaxoSmithKline, Merck, Natera Inc, Novartis, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Shionogi Inc, Xilio Therapeutics; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Dynavax Technologies, EMD Serono Inc, Genentech, a member of the Roche Group, Iovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics, Neon Therapeutics, Novartis.

    Jarushka Naidoo, MB BCH, MHS
    Consultant Medical Oncologist
    Beaumont Hospital
    Dublin, Ireland
    Adjunct Assistant Professor of Oncology
    Johns Hopkins University
    Baltimore, Maryland

    Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Merck, Pfizer Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Merck; Data and Safety Monitoring Board/Committee: Daiichi Sankyo Inc.

    Harvey I Pass, MD
    Stephen E Banner Professor of Thoracic Oncology
    Vice-Chairman, Research
    Department of Cardiothoracic Surgery
    Director, General Thoracic Surgery
    NYU Langone Medical Center
    New York, New York

    No relevant conflicts of interest to disclose

    Heather Wakelee, MD
    Professor of Medicine
    Chief, Division of Oncology
    Stanford University School of Medicine
    Deputy Director, Stanford Cancer Institute
    Stanford, California

    Advisory Board (Compensated): AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Daiichi Sankyo Inc, Helsinn Healthcare SA, Janssen Biotech Inc, Mirati Therapeutics, Xcovery; Advisory Board (Not Compensated): Cellworks, Genentech, a member of the Roche Group, Merck, Takeda Oncology; Research Funding to Institution: ACEA Biosciences Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics,AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, Xcovery.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    These activities are supported by an educational grant from Genentech, a member of the Roche Group.

    Release date: October 2021
    Expiration date: October 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio
(WIFI is recommended for best performance):